@adamfeuerstein Adam Feuerstein ✡️

Adam Feuerstein ✡️ posts on X about $ibrx, $hims, ceo, in the the most. They currently have [-------] followers and [---] posts still getting attention that total [------] engagements in the last [--] hours.

Engagements: [------] #

• [--] Week [---------] +132%
• [--] Month [---------] -62%
• [--] Months [----------] +107%
• [--] Year [----------] +104%

Mentions: [--] #

• [--] Week [---] +22%
• [--] Month [---] +36%
• [--] Months [---] +56%
• [--] Year [-----] +51%

Followers: [-------] #

• [--] Week [-------] +0.19%
• [--] Month [-------] +0.45%
• [--] Months [-------] +3.30%
• [--] Year [-------] +6.30%

CreatorRank: [-------] #

Social Influence

Social category influence stocks 45.04% finance 6.87% technology brands 2.29% countries 2.29% cryptocurrencies 0.76% social networks 0.76% musicians 0.76%

Social topic influence $ibrx #3, $hims #186, ceo 7.63%, in the 7.63%, $nvo #76, $ocul #14, $srpt #36, future 3.82%, food 3.82%, $amgn 3.82%

Top accounts mentioned or mentioned by @oshea9_harry @idenixh @drpatrick @matthewherper @salc7822 @lexliberty76 @pdsandiego @jaxyork72 @kinatsofrim @pharmalot @lizzylaw @elaineywchen @damiangarde @actionfixesfear @bullishbruk @tonysop87165701 @drewqjoseph @grok @alhmd120690 @plainyogurt21

Top assets mentioned ImmunityBio, Inc. Common Stock (IBRX) Hims & Hers Health, Inc. (HIMS) Novo-Nordisk (NVO) Ocular Therapeutix, Inc. (OCUL) Sarepta Therapeutics, Inc. (SRPT) Amgen, Inc. (AMGN) Synthetify (SNY) Eli Lilly and Company (LLY) Alnylam Pharmaceuticals, Inc. (ALNY) Revolution Medicines, Inc. (RVMD) Moderna Inc (MRNA) Gilead Sciences, Inc. (GILD) AbbVie Inc (ABBV) Sanofi (SNY) Intellia Therapeutics, Inc (NTLA) Novartis AG (NVS) Regeneron Pharmaceuticals Inc (REGN) Terns Pharmaceuticals, Inc. (TERN) Apogee Therapeutics, Inc. (APGE) Viking Therapeutics, Inc (VKTX) Arcellx, Inc. (ACLX) Ventyx Biosciences, Inc. (VTYX) Mineralys Therapeutics, Inc. (MLYS) Avidity Biosciences, Inc. (RNA) Caribou Biosciences, Inc. (CRBU) Dyne Therapeutics, Inc. (DYN) Kymera Therapeutics, Inc. (KYMR) BioMarin Pharmaceutical, Inc. (BMRN) Amicus Therapeutics, Inc (FOLD) Abivax SA (ABVX) Insmed, Inc. (INSM) GSK plc (GSK) CRISPR Therapeutics AG (CRSP) BEAM (BEAM) Bluefin (BLUE)

Top Social Posts

Top posts by engagements in the last [--] hours

"Finally @DrPatrick $IBRX needs to freshen up his cell therapy knowledge. This Lilly-Orna deal is the fourth acquisition of an in vivo CAR-T developer by a large drug maker behind Bristol Abbvie and Gilead Sciences. Notable none of these acquisitions focus on NK cell therapies. Why Because NK cell therapies have been studied already - and they don't work Big Pharma is finally waking up that cell therapies are the future of immunotherapy [---] https://t.co/3PuzztBIUZ Big Pharma is finally waking up that cell therapies are the future of immunotherapy [---] https://t.co/3PuzztBIUZ"
X Link 2026-02-09T21:53Z 124K followers, 25.2K engagements

"Story extensively updated. Prasad overruled FDA staff to reject Modernas flu vaccine application via @LizzyLaw_ https://www.statnews.com/2026/02/11/moderna-flu-vaccine-application-rejected-by-prasad-overruling-fda-staff/ https://www.statnews.com/2026/02/11/moderna-flu-vaccine-application-rejected-by-prasad-overruling-fda-staff/"
X Link 2026-02-11T21:19Z 124K followers, 42K engagements

"Paul Hudson out as Sanofi $SNY CEO via @DrewQJoseph https://www.statnews.com/2026/02/12/sanofi-ceo-replaced-paul-hudson-belen-garijo/ https://www.statnews.com/2026/02/12/sanofi-ceo-replaced-paul-hudson-belen-garijo/"
X Link 2026-02-12T10:48Z 124K followers, [----] engagements

"Who are your picks for Best and Worst Biopharma CEO of [----] Im putting together my lists. Who should I be considering Reply here or DM me. Thanks"
X Link 2025-11-09T19:43Z 124K followers, 41.4K engagements

"$NTLA update on FDA clinical hold should be imminent if not overdue already"
X Link 2025-12-01T21:49Z 124K followers, 16.3K engagements

"Eli Lilly $LLY reportedly in advanced discussions to acquire Ventyx Biosciences $VTYX for $1B+ -- wires Sad trombone"
X Link 2026-01-06T20:44Z 124K followers, 31.5K engagements

"A rival goes after Ocular Therapeutix $OCUL on eve of pivotal readout on eye treatment Eyepoint Pharma $EYPT CEO said to have trash-talked Oculars drug at a recent investor conference https://www.statnews.com/2026/02/05/ocular-therapeutix-eyepoint-pharmaceuticals/ https://www.statnews.com/2026/02/05/ocular-therapeutix-eyepoint-pharmaceuticals/"
X Link 2026-02-05T18:51Z 124K followers, 18K engagements

"@NicholasChoupak 100% agree with you. It's a very odd strategy for $EYPT to take. Duker should be cheering for $OCUL not trash talking"
X Link 2026-02-05T19:16Z 124K followers, [----] engagements

"Novo Nordisk $NVO accuses Hims & Hers $HIMS of illegal mass compounding over a cheaper version of Wegovy pill via @pharmalot @damiangarde https://www.statnews.com/pharmalot/2026/02/05/novo-weight-obesity-wegovy-hims-compounding-telehealth/ https://www.statnews.com/pharmalot/2026/02/05/novo-weight-obesity-wegovy-hims-compounding-telehealth/"
X Link 2026-02-05T20:54Z 124K followers, 10.2K engagements

"FDA rejects Regenxbios $RGNX rare-disease gene therapy Agency raised questions about the surrogate biomarker used to predict clinical benefit in Hunter syndrome https://www.statnews.com/2026/02/09/fda-rejects-regenxbio-rare-disease-gene-therapy/ https://www.statnews.com/2026/02/09/fda-rejects-regenxbio-rare-disease-gene-therapy/"
X Link 2026-02-09T21:26Z 124K followers, 16.7K engagements

"This week's Biotech Scorecard newsletter: Why biotechs future is threatened by zombies (Not the movie kind the money-wasting space-sucking negative EV kind) Link below"
X Link 2025-02-20T13:34Z 124K followers, 42K engagements

"Mineralys Therapeutics $MLYS stock soars on blood pressure drug data via @matthewherper https://www.statnews.com/2025/03/10/mineralys-therapeutics-blood-pressure-lorundrostat/ https://www.statnews.com/2025/03/10/mineralys-therapeutics-blood-pressure-lorundrostat/"
X Link 2025-03-10T14:32Z 124K followers, 10.2K engagements

"This week's Biotech Scorecard newsletter: Monopar $MNPR and the resurrection of a shelved drug for Wilson disease. It's a crazy story. AstraZeneca the drugs former owner terminated clinical development in [----] due to an inadvertent error made in a clinical trial. Monopar acquired the drug last year and then discovered the mistake made in a formula used to analyze copper elimination from the body. If approved possibly in the latter half of [----] the drug called ALXN1840 would be the first novel treatment for Wilson disease in [--] years. Monopar plans to submit for U.S. approval early next year"
X Link 2025-10-09T11:29Z 123.9K followers, 17.2K engagements

"Story link here: https://www.statnews.com/2025/09/11/soon-shiong-immunitybio-cancer-trial-results/ https://www.statnews.com/2025/09/11/soon-shiong-immunitybio-cancer-trial-results/"
X Link 2025-10-25T19:07Z 123.9K followers, 29.4K engagements

"$NVS buying $RNA $72 per share - $12B https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline"
X Link 2025-10-26T17:05Z 123.8K followers, 79.1K engagements

"Caribou Biosciences $CRBU said Monday that its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma. The study results while preliminary are comparable to benchmarks set by currently approved patient-specific CAR-T therapies for lymphoma an achievement that could push the off-the-shelf CAR-T field forward after years of setbacks and broaden access to cell therapy for blood cancers. https://www.statnews.com/2025/11/03/caribou-biosciences-vespa-cel-lymphoma/ https://www.statnews.com/2025/11/03/caribou-biosciences-vespa-cel-lymphoma/"
X Link 2025-11-03T12:01Z 123.9K followers, 23.9K engagements

"Hello #ASH25 attendees STAT is hosting a free live event tonight and you're all invited. We'll be talking about the future of hematology and oncology with execs from J&J Bristol and Gilead Sciences. Plus food and drinks Details here: https://www.statnews.com/event/stat-at-ash-2025/ https://www.statnews.com/event/stat-at-ash-2025/"
X Link 2025-12-05T17:33Z 123.9K followers, [----] engagements

"$DYN Dyne Therapeutics plans to file for approval for next-generation Duchenne drug. The medicine could be a more effective version of controversial Sarepta $SRPT drug via @Jasonmmast https://www.statnews.com/2025/12/08/dyne-therapeutics-duchenne-fda-exon-skipper-sarepta/ https://www.statnews.com/2025/12/08/dyne-therapeutics-duchenne-fda-exon-skipper-sarepta/"
X Link 2025-12-08T11:37Z 123.9K followers, 10.8K engagements

"Kymera $KYMR drug positioned to rival Sanofi and Regenerons Dupixent succeeds in early-stage eczema trial via @JonathanWosen $SNY $REGN https://www.statnews.com/2025/12/08/kymera-kt-621-clinical-trial-results-atopic-dermatitis-challenge-dupixent/ https://www.statnews.com/2025/12/08/kymera-kt-621-clinical-trial-results-atopic-dermatitis-challenge-dupixent/"
X Link 2025-12-08T12:01Z 123.9K followers, 13.5K engagements

"$TERN Results in Terns leukemia drug study suggest it could be a successor to Novartis $NVS blockbuster #ASH25 https://www.statnews.com/2025/12/08/terns-leukemia-drug-ash-results-tern-701/ https://www.statnews.com/2025/12/08/terns-leukemia-drug-ash-results-tern-701/"
X Link 2025-12-08T19:46Z 123.9K followers, 15.6K engagements

"$TERN investor dinner tonight in Orlando via Jefferies is standing room only. They ran out of seats and chicken stragglers only get dinner rolls thrown to them"
X Link 2025-12-08T21:43Z 124K followers, 16.9K engagements

"STAT @ #JPM26 housekeeping note: Register for our live event on Mon. evening Jan. [--]. On stage: Me in conversation w/ Rod Wong of RTW Investments and Agustin Mohedas from Janus Henderson. Two whipsmart biotech investors not to be missed. $ALNY CEO Yvonne Greenstreet fireside chatting with @matthewherper More details and register here: https://www.statnews.com/event/stat-at-jpm-live-event-2026/ https://www.statnews.com/event/stat-at-jpm-live-event-2026/"
X Link 2025-12-16T19:48Z 123.9K followers, 13K engagements

"$BMRN buying $FOLD $14.50 per share"
X Link 2025-12-19T12:47Z 123.9K followers, 11.6K engagements

"The $ABVX acquisition bubble popped. For now. There is no corporate lawyer on the planet Earth who would allow Abivaxs CEO to participate in this Jan. [--] event if a deal was imminent. Does this mean Abivax will never be acquired Of course not"
X Link 2025-12-30T15:42Z 123.9K followers, 50.6K engagements

"AI has finally started making drug-like antibodies. When will it revolutionize biopharma via @brittanytrang https://www.statnews.com/2026/01/06/will-artificial-intelligence-designed-drugs-antibodies-revolutionize-biopharma/ https://www.statnews.com/2026/01/06/will-artificial-intelligence-designed-drugs-antibodies-revolutionize-biopharma/"
X Link 2026-01-06T13:57Z 123.7K followers, [----] engagements

"I just read an $APGE sellside note that starts thusly: "Apogee proved that IL-13 works in asthma with up to a 60% reduction in FeNO." Apogee reported results from a Phase 1b study this morning. "Proved" I understand enthusiasm but let's retain some perspective please. My suggestion is broadly applicable. https://twitter.com/i/web/status/2008549409244524903 https://twitter.com/i/web/status/2008549409244524903"
X Link 2026-01-06T14:41Z 123.9K followers, 14.3K engagements

"$ABBV taking out $RVMD would certainly check the #JPM26 big M&A box. $20B plus deal"
X Link 2026-01-07T20:07Z 123.7K followers, 24K engagements

"Insmed $INSM basks in the success of its lung disease drug and prepares for whats next. I chatted Sunday with CEO Will Lewis before watching the Patriots beat the Chargers. #JPM26 https://www.statnews.com/2026/01/12/jpm-conference-insmed-brinsupri-bronchiectasis/ https://www.statnews.com/2026/01/12/jpm-conference-insmed-brinsupri-bronchiectasis/"
X Link 2026-01-12T14:16Z 123.7K followers, 11K engagements

"Reporting from inside the room. With a grin and tight lips Revolution Medicines $RVMD CEO faces questions about acquisition #JPM26 https://www.statnews.com/2026/01/12/revolution-medicines-merck-jpm-conference/ https://www.statnews.com/2026/01/12/revolution-medicines-merck-jpm-conference/"
X Link 2026-01-12T20:35Z 123.7K followers, 18.2K engagements

"So hows your #JPM26 been"
X Link 2026-01-14T22:17Z 123.9K followers, 25K engagements

"$IBRX Anktiva q/q sales growth slowed cash balance decreased. How much dilutive cash did the company raise from its adjusted ATM in January Classic: Issue lots of press releases pump stock higher sell stock. https://www.sec.gov/Archives/edgar/data/1326110/000119312525331244/d61833d8k.htm 700% increase in revenue. Over $200M cash on hand. Worlds first approval rescuing Checkpoint inhibitors in lung cancer. BCG naive trial enrolling like gangbusters. Patents issued with Checkpoint combinations till [----]. Quality of life. Healthspan. Unstoppable"
X Link 2026-01-15T15:54Z 123.9K followers, 23K engagements

"$GSK to buy $RAPT Therapeutics maker of food allergy treatment in $2.2B deal via @DrewQJoseph https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/ https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/"
X Link 2026-01-20T10:38Z 124K followers, 17.6K engagements

"Leerink's David Risinger on the $SNY amlitelimab Karposi's sarcoma case: "As a result we see risk of a potential black box warning on amlitelimabs label." Would be same for $AMGN $APGE and any other company with an OX40 drug right Perhaps I am over-reacting but doesn't the reported case of Kaposi's sarcoma in the $SNY amlitelimab atopic dermatitis study basically end any hope for the entire OX40 drug class $AMGN included. Why would any patient or physician take the risk with an OX40 drug when there are Perhaps I am over-reacting but doesn't the reported case of Kaposi's sarcoma in the $SNY"
X Link 2026-01-23T14:51Z 123.9K followers, 27.7K engagements

"Thank you Im particularly proud of my $SRPT work last year. Accountability journalism at its best. Im glad you recognize it. Over the past [--] months @adamfeuersteins X posts about Sarepta ( $SRPT ) show an unusually consistent and aggressive negative narrative - often echoing amplifying or previewing themes later used in STAT coverage. $SRPT $SLDB $RGNX $CRSP $EDIT $NTLA $BEAM $VRTX $REGN $BLUE https://t.co/N4noKK11no Over the past [--] months @adamfeuersteins X posts about Sarepta ( $SRPT ) show an unusually consistent and aggressive negative narrative - often echoing amplifying or previewing"
X Link 2026-01-23T23:25Z 124K followers, 20.5K engagements

"Yet @DrPatrick $IBRX fails to mention that with only [--] months of median follow up in these recurrent GBM patients making any claim about extended survival is nonsense especially when TTF therapy in these patients is proven to be modestly effective. (Median OS [--] months) Last August $IBRX reported response rates from [--] patients in this study. Yesterdays release with [--] evaluable patients - no disclosure of response results. Selective inconsistent data releases are a red flag. $IBRX I couldn't get that Press Release from Friday out of my head. So I asked Grok to explain it to me. I was"
X Link 2026-01-24T20:23Z 124K followers, 56.2K engagements

"WSJ: $MRK $RVMD deal off https://www.wsj.com/health/pharma/merck-no-longer-in-talks-to-buy-revolution-medicines-b8d5e5ebgaa_at=eafs&gaa_n=AWEtsqfi0XLjcBZ4vuhwFUZ3Kfpu8Qidy79o1rLvJ8CcMPL986zHwOG6KG0L3g9UsPg%3D&gaa_ts=69767825&gaa_sig=MrZgSUGW2oQoYVC-o0Q6-xe6c4NWo_YlIDO-W5Xp4nOqK1kMtdIbhRLAJc84ZDDyEUFPG0k0iuP6ck9qLNP9Tw%3D%3D"
X Link 2026-01-25T19:56Z 123.7K followers, 54.5K engagements

"In this morning's press release this is all that $SRPT discloses about Elevidys safety one year after liver toxicity liver-injury related hospitalizations and deaths due to acute liver failure nearly ended the gene therapy. "No new treatment-related safety signals were observed reinforcing the consistent and manageable safety profile seen in ambulatory patients treated with ELEVIDYS to date." https://twitter.com/i/web/status/2015774404265816170 https://twitter.com/i/web/status/2015774404265816170"
X Link 2026-01-26T13:10Z 123.8K followers, 22.6K engagements

"Roche moves obesity drug to pivotal trials after mid-stage success via @DrewQJoseph https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/ https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/"
X Link 2026-01-27T10:37Z 123.9K followers, 10.8K engagements

"Whos going to tell him @adamfeuerstein Ive been trading biotechs since November to the long side and either Im really good or its really easy or both 😅😅😅😅 The lull is welcome as long as its a pause in the eye of the mighty $XbI before the next storm up oblitering every short account mercilessly @adamfeuerstein Ive been trading biotechs since November to the long side and either Im really good or its really easy or both 😅😅😅😅 The lull is welcome as long as its a pause in the eye of the mighty $XbI before the next storm up oblitering every short account mercilessly"
X Link 2026-01-28T01:21Z 123.9K followers, 65.5K engagements

"$RGNX A question that is likely to come up today -- How different or similar are the MPS gene therapies to RGX-202 its gene therapy for DMD I asked the company: "RGX-202 which is in pivotal study for Duchenne is a completely different therapy than either RGX-121 or RGX-111. RGX-202 uses systemic delivery of a novel construct that includes the AAV8 vector a microdystrophin with the CT domain and different promoter. We have seen no SAEs or AESIs in the Phase I/II trial of RGX-202. RGX-121 and RGX-111 use AAV9." BREAKING: FDA halts $RGNX gene therapy trials after brain tumor found in patient."
X Link 2026-01-28T12:45Z 124K followers, 16.4K engagements

"In this week's Biotech Scorecard newsletter: $IBRX ImmunityBio and its Chairman Patrick Soon-Shiong @DrPatrick mischaracterized talks with FDA over expanding use of Anktiva its bladder cancer drug sources told me. Publicly $IBRX and Soon-Shiong have claimed the FDA unanimously endorsed the Anktiva data after a January [----] meeting and unambiguously invited the company to file an application for the papillary bladder cancer indication. I spoke to people familiar with the FDA involvement in this January [----] meeting. They told me: At no point during or after the January [----] meeting with"
X Link 2026-01-29T13:03Z 123.9K followers, 27.4K engagements

"Show of hands how many $IBRX @DrPatrick acolytes on this platform are antisemites Be honest most of you basement-dwelling cowards post anonymously anyway. Yes I am No but I do hate Jews Yes I am No but I do hate Jews"
X Link 2026-01-30T00:34Z 123.9K followers, 15.4K engagements

"What's this about EMA re-reviewing $AMGN Tavneos due to "data integrity" issues in study that supported approval. https://www.ema.europa.eu/en/news/ema-starts-review-tavneos-medicine-rare-autoimmune-diseases-gpa-mpa https://www.ema.europa.eu/en/news/ema-starts-review-tavneos-medicine-rare-autoimmune-diseases-gpa-mpa"
X Link 2026-01-30T12:47Z 123.9K followers, 13.9K engagements

"And now $AMGN returns its OX40 drug candidate rocatinlimab to Kyowa. Perhaps I am over-reacting but doesn't the reported case of Kaposi's sarcoma in the $SNY amlitelimab atopic dermatitis study basically end any hope for the entire OX40 drug class $AMGN included. Why would any patient or physician take the risk with an OX40 drug when there are Perhaps I am over-reacting but doesn't the reported case of Kaposi's sarcoma in the $SNY amlitelimab atopic dermatitis study basically end any hope for the entire OX40 drug class $AMGN included. Why would any patient or physician take the risk with an"
X Link 2026-01-30T14:31Z 123.8K followers, 40.2K engagements

"This is the Grade [--] SAE version of "our partner doesn't like or want our drug so they gave it back." Wave Life Sciences $WVE announces plans to accelerate regulatory engagement with full control of WVE-006 for alpha-1 antitrypsin deficiency"
X Link 2026-02-02T12:45Z 123.9K followers, 17.7K engagements

"Another OX40 update and it's not good. On an analyst call Sunday Kyowa Kirin disclosed a case of Karposi's sarcoma with rocatinlimab in a "high risk" patient according to a Jefferies note. Recall last week $AMGN returned roca to Kyowa"
X Link 2026-02-02T12:52Z 123.9K followers, 52.4K engagements

"$IBRX NK cell therapy showing 50% durable CR rate in indolent NHL (and just WM) is suboptimal lower than competing allogeneic and autologous CAR-Ts. $IBRX Announced they may have just found a "functional cure" for Waldenstrms Macroglobulinemia (a rare lymphoma). They achieved a 100% disease control in a small study of [--] patients. Phase-2 trial just approved. https://t.co/7U9Vgh2HLS $IBRX Announced they may have just found a "functional cure" for Waldenstrms Macroglobulinemia (a rare lymphoma). They achieved a 100% disease control in a small study of [--] patients. Phase-2 trial just approved."
X Link 2026-02-02T15:27Z 123.9K followers, 22K engagements

"@pdsandiego Correct. Those benchmarks include conditioning but a $IBRX non-conditioning regimen with suboptimal remission rates will be a non-starter"
X Link 2026-02-02T17:59Z 123.9K followers, [---] engagements

"@biotraderusa Reporting n=4 is highly misleading but that's what $IBRX chose to do"
X Link 2026-02-02T18:11Z 123.9K followers, [---] engagements

"Pfizer $PFE obesity drug data https://www.businesswire.com/news/home/20260202566685/en/Pfizers-Ultra-Long-Acting-Injectable-GLP-1-RA-Shows-Robust-and-Continued-Weight-Loss-with-Monthly-Dosing-in-Phase-2b-Trial https://www.businesswire.com/news/home/20260202566685/en/Pfizers-Ultra-Long-Acting-Injectable-GLP-1-RA-Shows-Robust-and-Continued-Weight-Loss-with-Monthly-Dosing-in-Phase-2b-Trial"
X Link 2026-02-03T11:43Z 123.9K followers, 22.6K engagements

"$NVO down sharply on early release of earnings including weaker-than-expected sales guidance for 2026"
X Link 2026-02-03T17:05Z 123.9K followers, 13.7K engagements

"Novo Nordisk $NVO lowers sales profits forecast as Wegovy faces growing competition via @elaineywchen https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/ https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/"
X Link 2026-02-03T17:39Z 123.9K followers, [----] engagements

"@Sanctuary_Bio You know Amgen's lawyers love a good fight even when it's not worth the effort. (I guess the billable hours matter.)"
X Link 2026-02-03T21:26Z 123.9K followers, [----] engagements

"$LLY strong earnings and '26 guidance. Guidance: Adjusted EPS $33.50-35.00 vs consensus $33.04. Revenue: $80-83B vs consensus $77.64B"
X Link 2026-02-04T11:57Z 123.9K followers, 32.4K engagements

"@Biohazard3737 Because $VKTX is none of those things"
X Link 2026-02-04T13:32Z 123.9K followers, [----] engagements

"Let's blame $EIKN for this"
X Link 2026-02-05T20:32Z 124K followers, 13K engagements

"$HIMS FDA will take swift action against companies mass-marketing illegal copycat drugs claiming they are similar to FDA-approved products. The FDA cannot verify the quality safety or effectiveness of non-approved drugs. FDA will take swift action against companies mass-marketing illegal copycat drugs claiming they are similar to FDA-approved products. The FDA cannot verify the quality safety or effectiveness of non-approved drugs"
X Link 2026-02-05T23:26Z 123.9K followers, 23.7K engagements

"$HIMS should be shut down. Based on a review of the applicable facts earlier today @HHSOGC referred Hims & Hers Health Inc. (Hims) to the Department of Justice for investigation for potential violations by Hims of the Federal Food Drug and Cosmetic Act and applicable Title [--] provisions. Based on a review of the applicable facts earlier today @HHSOGC referred Hims & Hers Health Inc. (Hims) to the Department of Justice for investigation for potential violations by Hims of the Federal Food Drug and Cosmetic Act and applicable Title [--] provisions"
X Link 2026-02-06T21:40Z 123.9K followers, 126.5K engagements

"HHS asks Justice Department to probe Hims & Hers $HIMS over its cheaper compounded version of $NVO Wegovy via @pharmalot https://www.statnews.com/pharmalot/2026/02/06/fda-take-action-against-hims-telehealth-wegovy-compounding/ https://www.statnews.com/pharmalot/2026/02/06/fda-take-action-against-hims-telehealth-wegovy-compounding/"
X Link 2026-02-07T01:16Z 123.9K followers, 15.7K engagements

"@Sanctuary_Bio @alc2022 Same idiot touting $IBRX will save the world"
X Link 2026-02-07T01:36Z 123.9K followers, [----] engagements

"Biotech investing is rife with this behavior. X Reddit Discord amplify it. $HIMS is a good case study in why you should never become emotionally attached to a stock. Always stay open-minded and be willing to change your thesis when the facts change. And just as important dont let certain accounts here brainwash you into ignoring the warning signs. $HIMS is a good case study in why you should never become emotionally attached to a stock. Always stay open-minded and be willing to change your thesis when the facts change. And just as important dont let certain accounts here brainwash you into"
X Link 2026-02-07T17:10Z 123.9K followers, 25.5K engagements

"we have decided 🤣 $HIMS Since launching the compounded semaglutide pill on our platform weve had constructive conversations with stakeholders across the industry. As a result we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us Since launching the compounded semaglutide pill on our platform weve had constructive conversations with stakeholders across the industry. As a result we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us"
X Link 2026-02-07T20:05Z 123.9K followers, 31.7K engagements

"Hims & Hers $HIMS will stop selling compounded version of Novos obesity pill via @elaineywchen https://www.statnews.com/2026/02/07/hims-wont-sell-compounded-obesity-pill-novo/ https://www.statnews.com/2026/02/07/hims-wont-sell-compounded-obesity-pill-novo/"
X Link 2026-02-07T21:17Z 123.9K followers, [----] engagements

"Who listens to this idiot Odds are very high that every human on Earth needs to take $IBRX Anktiva several times in their life. Ozempic has made $NVO a $300B company. Anktiva can make $IBRX a $1T company. Odds are very high that every human on Earth needs to take $IBRX Anktiva several times in their life. Ozempic has made $NVO a $300B company. Anktiva can make $IBRX a $1T company"
X Link 2026-02-08T00:40Z 123.9K followers, 33.4K engagements

"Innovent (China) - $LLY oncology / immunology research collaboration Under the terms of the agreement Innovent will receive a $350 million upfront payment and is eligible to receive development regulatory and commercial milestone payments totaling up to approximately $8.5 billion contingent upon the achievement of certain future events. Additionally Innovent will be eligible for tiered royalties on net sales of each product outside of Greater China. https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetailkey=578 https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetailkey=578"
X Link 2026-02-08T12:34Z 123.9K followers, 13.5K engagements

"The grifter nexus between $HIMS and $IBRX I wonder if $IBRX and $HIMS ever see their paths cross in the future. Think about it $HIMS has launched labs which can measure a customer's overall health status. They're also moving into segments such as longevity. I think the market is viewing Anktiva wrongly because we're I wonder if $IBRX and $HIMS ever see their paths cross in the future. Think about it $HIMS has launched labs which can measure a customer's overall health status. They're also moving into segments such as longevity. I think the market is viewing Anktiva wrongly because we're"
X Link 2026-02-08T13:35Z 123.9K followers, 22.5K engagements

"Green Day Bad Bunny for halftime show"
X Link 2026-02-08T23:08Z 123.9K followers, 17.1K engagements

"You know whats un-American Ill tell you. Companies that offer embargoed Monday news during the Super Bowl. Im not kidding"
X Link 2026-02-09T02:00Z 123.9K followers, 47K engagements

"$RGNX Hunter syndrome gene therapy rejected by FDA"
X Link 2026-02-09T21:12Z 124K followers, 16.5K engagements

"My story: Eczema drug from Nektar Therapeutics $NKTR maintains skin responses in one-year study https://www.statnews.com/2026/02/10/nektar-therapeutics-rezpeg-eczema-drug-maintains-skin-response-study/ https://www.statnews.com/2026/02/10/nektar-therapeutics-rezpeg-eczema-drug-maintains-skin-response-study/"
X Link 2026-02-10T12:02Z 124K followers, [----] engagements

"And here's the $NKTR press release: https://ir.nektar.com/news-releases/news-release-details/new-rezolve-ad-maintenance-data-atopic-dermatitis-demonstrate https://ir.nektar.com/news-releases/news-release-details/new-rezolve-ad-maintenance-data-atopic-dermatitis-demonstrate"
X Link 2026-02-10T12:02Z 123.9K followers, [----] engagements

"RT @A_May_MD: The table below is something I built and have been using lately to reaffirm to myself that $NKTRs current valuation is just"
X Link 2026-02-10T15:17Z 123.9K followers, [--] engagements

"$NKTR raising $300M in stock and pre-funded warrants https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-proposed-public-offering-0 https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-proposed-public-offering-0"
X Link 2026-02-10T21:21Z 124K followers, 12.7K engagements

"@salc7822 @DrPatrick You believe Anktiva sales in Saudi Arabia will be material Can you list other drug makers who rush to enter the Saudi market before they meaningfully penetrate the US EU Asia markets"
X Link 2026-02-10T21:47Z 123.9K followers, [---] engagements

"@salc7822 @DrPatrick Ah Clinical trial results that demonstrate a benefit would be helpful. Do you see $IBRX completing any of its studies in the near term"
X Link 2026-02-10T21:48Z 124K followers, [----] engagements

"@JaxYork72 @DrPatrick versus real materially beneficial market expansion in the US"
X Link 2026-02-10T21:50Z 123.9K followers, [---] engagements

"@salc7822 @DrPatrick I do. The Saudi strategy is intended to divert attention away from $IBRX regularly failures here and delays in completing clinical trials"
X Link 2026-02-10T22:56Z 123.9K followers, [---] engagements

"@CloisterRes I have raised this concern. Its real"
X Link 2026-02-11T14:56Z 124K followers, [----] engagements

"@pdsandiego @Oshin76 Paul - My apologies. Youre not very bright. Next time I will use simpler words and concepts"
X Link 2026-02-12T23:50Z 124K followers, [---] engagements

"Sareptas $SRPT dismal quarter marred by drug failures and a long list of excuses https://www.statnews.com/2025/11/04/sarepta-therapeutics-duchenne-trials-earnings/ https://www.statnews.com/2025/11/04/sarepta-therapeutics-duchenne-trials-earnings/"
X Link 2025-11-04T12:50Z 124K followers, 10.6K engagements

"This week's Biotech Scorecard newsletter: Richard Pazdur surely has many items on his to-do list now that hes the top drug regulator at the Food and Drug Administration. One of the decisions he will soon help make how to deal with the dangling accelerated approvals given to Sarepta Therapeutics $SRPT for its Duchenne muscular dystrophy drugs will tell us a lot about how much independence and scientific rigor Pazdur intends to bring to the new job"
X Link 2025-11-20T15:03Z 124K followers, 12.1K engagements

"Also my gratitude list for [----]. https://www.statnews.com/2025/11/20/fda-sarepta-therapeutics-richard-pazdur-duchenne/ https://www.statnews.com/2025/11/20/fda-sarepta-therapeutics-richard-pazdur-duchenne/"
X Link 2025-11-20T15:03Z 124K followers, [----] engagements

"$ACLX sold off on the Kelonia Therapeutics (private) #ASH25 LBA1 in vivo BCMA CAR-T for multiple myeloma"
X Link 2025-11-24T17:50Z 124K followers, 30.5K engagements

"Here is Vinay Prasad's memo/email in full laying out the FDA's new vaccine policy. ------ From: Prasad Vinayak Vinayak.Prasad@fda.hhs.gov Sent: Friday November [--] [----] 4:21 PM To: CBER-SUBSCRIBERS-ALL CBER-SUBSCRIBERS-ALL@fda.hhs.gov Subject: Deaths in children due to COVID-19 vaccines and CBER's path forward Dear Team CBER I am writing to report that OBPV career staff have found that at least [--] children have died after and because of receiving COVID-19 vaccination. These deaths are related to vaccination (likely/probable/possible attribution made by staff). That number is certainly an"
X Link 2025-11-29T21:43Z 124K followers, 200.5K engagements

"New data from Gilead Arcellx multiple myeloma CAR-T suggest benefit over rival treatment $GILD $ACLX $JNJ $LEGN #ASH25 https://www.statnews.com/2025/12/07/gilead-arcellx-multiple-myeloma-treatment-anito-cel-promising-data-ash/ https://www.statnews.com/2025/12/07/gilead-arcellx-multiple-myeloma-treatment-anito-cel-promising-data-ash/"
X Link 2025-12-07T16:00Z 124K followers, 16.2K engagements

"The Worst Biopharma CEO of [----] made decisions with tragic consequences Doug Ingram Sarepta Therapeutics. $SRPT Is anyone surprised Does anyone disagree https://www.statnews.com/2025/12/17/worst-biopharma-ceo-2025-doug-ingram-sarepta-therapeutics/ https://www.statnews.com/2025/12/17/worst-biopharma-ceo-2025-doug-ingram-sarepta-therapeutics/"
X Link 2025-12-17T13:51Z 124K followers, 27.3K engagements

"Today STAT is revealing a surprise addition to the speaker roster for our #JPM26 event on Mon. Jan. 12: Richard Pazdur. We've also released another batch of tickets. Register now https://www.statnews.com/event/stat-at-jpm-live-event-2026/ https://www.statnews.com/event/stat-at-jpm-live-event-2026/"
X Link 2026-01-02T17:47Z 124K followers, 17.7K engagements

"Here's the full lineup for the STAT @ JPM26 event: -- $ALNY CEO Yvonne Greenstreet w/ @matthewherper -- Rod Wong (RTW ) and Agustin Mohedas (Janus Henderson) w/ me. -- Scott Gottlieb Richard Pazdur and Julie Tierney w/ Matt. https://www.statnews.com/event/stat-at-jpm-live-event-2026/ https://www.statnews.com/event/stat-at-jpm-live-event-2026/"
X Link 2026-01-02T17:47Z 124K followers, [----] engagements

"This week's Biotech Scorecard newsletter: Ocular Therapeutix $OCUL faces looming test of a more durable eye treatment. A preview of the Axpaxli SOL-1 clinical trial readout expected in February https://www.statnews.com/2026/01/08/ocular-therapeutix-wet-amd-axpaxli/ https://www.statnews.com/2026/01/08/ocular-therapeutix-wet-amd-axpaxli/"
X Link 2026-01-08T15:03Z 124K followers, 10.3K engagements

"$ALNY With ambitious five-year plan Alnylam tells investors: trust us via @matthewherper #JPM26 https://www.statnews.com/2026/01/11/alnylam-five-year-plan-amvuttra-investors-jpm-2026/ https://www.statnews.com/2026/01/11/alnylam-five-year-plan-amvuttra-investors-jpm-2026/"
X Link 2026-01-11T22:04Z 124K followers, 22.8K engagements

"On this week's Readout LOUD podcast: We chatted withLauren Holder @laurencurehd about $QURE AMT-130 and the FDA. Lauren is a Huntington's disease patient advocate and is herself living with the disease. This interview is well worth your time. The Readout LOUD is available for streaming on all podcast platforms. https://www.statnews.com/2026/01/29/readout-loud-podcast-huntingtons-patients-uniqure-gene-therapy/ https://www.statnews.com/2026/01/29/readout-loud-podcast-huntingtons-patients-uniqure-gene-therapy/"
X Link 2026-01-30T14:19Z 124K followers, 17.9K engagements

"@BiotechPort Can you define $OCUL fail No stat sig difference in maintenance of visual acuity at [--] months Or the benefit is too marginal"
X Link 2026-01-31T19:04Z 124K followers, [----] engagements

"$BMY Patent expirations and recent pipeline setbacks has made the outcome of the Cobenfy Ph3 study in Alzheimer's agitation a crucial moment for Bristol Myers Squibb. @damiangarde reports. https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/ https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/"
X Link 2026-02-02T14:06Z 124K followers, 10.2K engagements

"$SGMO fired its principal financial officer https://www.sec.gov/ixdoc=/Archives/edgar/data/1001233/000100123326000002/sgmo-20260202.htm https://www.sec.gov/ixdoc=/Archives/edgar/data/1001233/000100123326000002/sgmo-20260202.htm"
X Link 2026-02-03T14:10Z 124K followers, 23.8K engagements

"$AMGN Tavneos update. FDA wants it pulled from the market. On January [--] [----] the U.S. Food and Drug Administration (FDA) requested that ChemoCentryx voluntarily withdraw TAVNEOS from the U.S. market. The FDA raised concerns about the process followed by ChemoCentryx to re-adjudicate primary endpoint results for [--] of the [---] patients in its pivotal clinical trial. Hepatotoxicity which is a known infrequent risk of TAVNEOS treatment for AAV was also raised in the context of the benefit-risk profile of the medicine. Amgen is not aware of any issue with the underlying patient data from the"
X Link 2026-02-03T21:10Z 124K followers, 15K engagements

"$OCUL earnings posted this morning plus an Axpaxli SOL-1 trial update. Topline results will be announced in the "second half of February" the company said today. The study will then be presented at the Macula Society mtg Feb 25-28. "To date the SOL-1 trial results remain masked." https://twitter.com/i/web/status/2019383809771221148 https://twitter.com/i/web/status/2019383809771221148"
X Link 2026-02-05T12:13Z 124K followers, 13.6K engagements

"Nektar Therapeutics $NKTR is trying to stage a comeback. But a big test awaits https://www.statnews.com/2026/02/05/nektar-therapeutics-eczema-atopic-dermatitis-rezpeg/ https://www.statnews.com/2026/02/05/nektar-therapeutics-eczema-atopic-dermatitis-rezpeg/"
X Link 2026-02-05T13:53Z 124K followers, 13.4K engagements

"BREAKING: Novo Nordisk $NVO sues Hims & Hers $HIMS for infringing on a key Wegovy patent via @pharmalot https://www.statnews.com/pharmalot/2026/02/09/novo-sues-hims-infringing-wegovy-patent-obesity/ https://www.statnews.com/pharmalot/2026/02/09/novo-sues-hims-infringing-wegovy-patent-obesity/"
X Link 2026-02-09T12:02Z 124K followers, 52.6K engagements

"Eli Lilly $LLY to buy Orna Therapeutics (private) for $2.4 billion. Circular RNA CAR-T therapies. via @matthewherper https://www.statnews.com/2026/02/09/eli-lilly-buys-orna-therapeutics-in-vivo-car-t/ https://www.statnews.com/2026/02/09/eli-lilly-buys-orna-therapeutics-in-vivo-car-t/"
X Link 2026-02-09T12:05Z 124K followers, 20.4K engagements

"@pdsandiego Incorrect. $IBRX has run afoul of the FDA bc it didn't follow the agency's clearly stated guidance for papillary bladder cancer. The FDA didn't move the goalpost @DrPatrick decided the goalpost didn't matter"
X Link 2026-02-12T16:38Z 124K followers, [---] engagements

"@pdsandiego @DrPatrick Merck's initial approval in the MSI-H/dmmr pathway was conducted in patients with refractory disease. It has since conducted RCTs in newly diagnosed patients. Example: $IBRX obtained its Anktiva CIS bladder approval via a single-arm study. https://www.nejm.org/doi/full/10.1056/NEJMoa2017699 https://www.nejm.org/doi/full/10.1056/NEJMoa2017699"
X Link 2026-02-12T20:15Z 124K followers, [---] engagements

"@DotknightWang @NoMonkeyBusine4 @DrPatrick You may not be aware but "Bioshield" is just a gimmicky marketing slogan. The FDA is not going to approve "Bioshield" because it doesn't exist"
X Link 2026-02-12T22:21Z 124K followers, [--] engagements

"BREAKING: Private jets owned by every pharma company in the world have been landing in the SF Bay Area all day. Something is happening"
X Link 2026-01-11T22:49Z 124K followers, 4.5M engagements

"FDA Commissioner Marty Makary tried to give Compass Pathways $CMPS one of his priority vouchers for its psychedelic drug. The Trump White House said no. Reporting from @LizzyLaw_ @elaineywchen @damiangarde https://www.statnews.com/2026/02/04/psilocybin-depression-psychedelic-drug-fast-track-blocked/ https://www.statnews.com/2026/02/04/psilocybin-depression-psychedelic-drug-fast-track-blocked/"
X Link 2026-02-04T14:01Z 124K followers, 26.9K engagements

"I received a strongly worded statement from $OCUL The rumors that are circulating alleging that we have seen the unmasked results from the SOL-1 trial or have knowledge that the trial did not succeed are categorically false." More in the story"
X Link 2026-02-05T18:53Z 124K followers, 29.6K engagements

"Lawsuit against Hims & Hers should be wake-up call for compounders Novo chief counsel tells STAT in exclusive interview. $NVO $HIMS via @elaineywchen @pharmalot https://www.statnews.com/2026/02/09/hims-novo-lawsuit-chief-counsel-interview/ https://www.statnews.com/2026/02/09/hims-novo-lawsuit-chief-counsel-interview/"
X Link 2026-02-09T14:17Z 124K followers, 32.9K engagements

"$NVO general counsel says in our interview: $HIMS relies on "sham mass personalization of semaglutide." HIMS' attempt to sell a compounded version of the Wegovy pill is "like the old days of snake oil salesmen just selling things out on the road.It's hard to believe that's where we've gotten." "This is completely out of control at this point where companies feel emboldened to put untested unapproved medicines and represent them to the public." Read the full interview below. Lawsuit against Hims & Hers should be wake-up call for compounders Novo chief counsel tells STAT in exclusive interview."
X Link 2026-02-09T14:42Z 124K followers, 20.5K engagements

"$NKTR here we go Rezpeg maintenance data in atopic dermatitis. The big picture: 71% of patients on monthly rezpeg maintained their induction EASI75 response at one year. 83% of patients on quarterly rezpeg achieved the same. My (non-expert) view: The results from Nektars maintenance study met and in some cases exceeded investor expectations positioning rezpeg as a treatment with the potential to compete strongly against Dupixent and Ebglyst. Im eager to hear how @A_May_MD (actual expert) sees the rezpeg maintenance study results. I assume hell opine shortly. I spoke to the Nektar folks last"
X Link 2026-02-10T12:02Z 124K followers, 28.5K engagements

"How does $IBRX benefit from the Saudi FDA approval of Anktiva What say the fanboys/girls of @DrPatrick on this question I'm not talking about the stock price so spare me that reply. What material benefit will ImmunityBio gain from focusing on Saudi Arabia"
X Link 2026-02-10T21:05Z 124K followers, 23.7K engagements

"Prasad overruled FDA staff to reject Modernas flu vaccine application via @lizzylaw https://www.statnews.com/2026/02/11/moderna-flu-vaccine-application-rejected-by-prasad-overruling-fda-staff/ https://www.statnews.com/2026/02/11/moderna-flu-vaccine-application-rejected-by-prasad-overruling-fda-staff/"
X Link 2026-02-11T15:33Z 124K followers, 34.7K engagements

"This week's Biotech Scorecard newsletter: The old Vinay Prasad never left. He just changed jobs Submissions to the FDA are handled by teams of reviewers of course. But when I look across all of these recent cases I see a consistent throwback to the old Prasad questioning the legitimacy of biomarkers surrogate endpoints and single-arm clinical trials even in the setting of rare diseases. In some of these rare-disease drug rejections Atara $ATRA and Regenxbio $RGNX are good examples Prasad or the staffers he directs arent following the agencys own guidance. Companies are told early that their"
X Link 2026-02-12T15:08Z 124K followers, 38.9K engagements

"FDA rejects rare disease therapy from $IRON Disc Medicine early recipient of commissioners voucher CNPV program falters out of the starting gate. via @LizzyLaw_ and me https://www.statnews.com/2026/02/13/disc-medicine-fda-decision/ https://www.statnews.com/2026/02/13/disc-medicine-fda-decision/"
X Link 2026-02-13T20:30Z 124K followers, 17.1K engagements

"@hema_Toma @DrPatrick Anktiva is an approved drug. Any oncologist can prescribe it off label if they believed it would help their patient. Insurance wont pay for it of course and it costs $36K per month. Anktiva is not used commonly off label bc there is no substantial evidence it helps patients"
X Link 2026-02-15T15:17Z 124K followers, [---] engagements

"Friends - My humble request is that you sign up for the email version of my weekly newsletter. Its contents are also posted on STAT's website but the email arrives every Thursday at 6:30 am ET which means you can hate-read it over coffee. https://www.statnews.com/signup/scorecard/ https://www.statnews.com/signup/scorecard/"
X Link 2024-10-24T14:34Z 124K followers, 416.9K engagements

"$SLNO is repurchasing $100M of its stock. Strong move. https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-entry-100-million-accelerated https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-entry-100-million-accelerated"
X Link 2025-11-11T12:05Z 124K followers, 37.4K engagements

"This might sound mean and simplistically stupid but is it possible the problem is $VKTX CEO Brian Lian You know the saying "He could sell ice to eskimos." Brian is the opposite of that. Forget about selling I don't know if Brian could give away a glass of water to a man dying of thirst. Maybe Viking needs a messaging revamp. Free advice. https://twitter.com/i/web/status/2019074495512764832 https://twitter.com/i/web/status/2019074495512764832"
X Link 2026-02-04T15:44Z 124K followers, 17.5K engagements

"BREAKING: FDA refuses to review Modernas $MRNA influenza vaccine via @matthewherper https://www.statnews.com/2026/02/10/fda-refuses-review-moderna-flu-vaccine-application/ https://www.statnews.com/2026/02/10/fda-refuses-review-moderna-flu-vaccine-application/"
X Link 2026-02-10T23:03Z 124K followers, 29.5K engagements

"BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase [--] success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. via @damiangarde https://www.statnews.com/2026/02/12/bridgebio-dwarfism-achondroplasia-infigratinib/ https://www.statnews.com/2026/02/12/bridgebio-dwarfism-achondroplasia-infigratinib/"
X Link 2026-02-12T12:37Z 124K followers, 29.9K engagements

"The old Vinay Prasad never left. He just changed jobs Beyond vaccines the FDA official appears to be taking a conservative approach to rare disease drugs https://www.statnews.com/2026/02/12/prasad-takes-conservative-approach-rare-disease-drugs-adams-biotech-scorecard/ https://www.statnews.com/2026/02/12/prasad-takes-conservative-approach-rare-disease-drugs-adams-biotech-scorecard/"
X Link 2026-02-12T15:08Z 124K followers, 19K engagements

"We just finished recording this week's Readout LOUD podcast focused entirely on the FDA (Vinay Prasad) decision to block a review of $MRNA 's flu vaccine. You'll hear directly from Moderna President Stephen Hoge and former FDA official Jesse Goodman. @matthewherper and @LizzyLaw_ also joined us. The episode will drop later today"
X Link 2026-02-12T16:24Z 124K followers, [----] engagements

"It would be highly instructive to read the pembrolizumab paper highlighted by @DrPatrick. Of course he doesn't expect anyone to do that. This is what it says IN THE FIRST PARAGRAPH: The FDA approved pembrolizumab on May [--] [----] for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and for the treatment of unresectable or metastatic MSI-H or dMMR colorectal cancer that has"
X Link 2026-02-12T18:18Z 124K followers, 24.7K engagements

"Modernas $MRNA president weighs in on FDAs decision not to review its flu vaccine Transcript of our interview w/ Stephen Hoge. You can listen to the interview as part of this week's Readout LOUD podcast available on all pod platforms. via @statnews https://www.statnews.com/2026/02/12/moderna-stephen-hoge-interview-flu-vaccine/ https://www.statnews.com/2026/02/12/moderna-stephen-hoge-interview-flu-vaccine/"
X Link 2026-02-13T12:46Z 124K followers, [----] engagements

"Actually scary that this man has an MD after his name. That slide is even worse than the NEJM KM curves with the truncated y-axis graph inserted on the proper graph. Now show me the curves without massively truncating the y-axis Thank goodness Vinay is at FDA That slide is even worse than the NEJM KM curves with the truncated y-axis graph inserted on the proper graph. Now show me the curves without massively truncating the y-axis Thank goodness Vinay is at FDA"
X Link 2026-02-14T01:56Z 124K followers, 77K engagements

"RT @docrodwong: last year's data show orphan disease rejections were up approvals down. and early rejections this year (atara ptld ultra"
X Link 2026-02-14T12:44Z 124K followers, [---] engagements

"Im just a dog lover. 🐶"
X Link 2026-02-14T13:07Z 124K followers, [----] engagements

"RT @pemulisking: Ok"
X Link 2026-02-14T19:23Z 124K followers, [---] engagements

"Last night John Dont truncate the Y axis Mandrola posted a graph with a truncated Y axis. Good morning everyone @drjohnm Even a better example: Generic 4$ per month spironolactone in HFrEF is so good it does not require a doctored graph. https://t.co/E0kE08QdtU Even a better example: Generic 4$ per month spironolactone in HFrEF is so good it does not require a doctored graph. https://t.co/E0kE08QdtU"
X Link 2026-02-15T12:22Z 124K followers, 53.4K engagements

"This is not a Saudi-USA Biotech Alliance its a Saudi @DrPatrick $IBRX you pay we pay marketing campaign. Anktiva is stalled in the US because he cant generate the clinical data to move the drug forward so he goes to the Middle East where standards are more transactional than science based. Just Arrived in Riyadh as a guest of the nation's leadership to share clinical breakthroughs that could transform healthcare in the Middle East. The Saudi-USA Biotech Alliance in action. The era of immunotherapy [---] has started with the first approval of ANKTIVA + checkpoint https://t.co/UGGAdCeExn Just"
X Link 2026-02-15T14:45Z 124K followers, 26.1K engagements

"@firebutworking $OCUL BCVA data from SOL-1 equally important bc it translates more to how wet AMD is treated"
X Link 2026-02-15T14:48Z 124K followers, [----] engagements

"Adam youre such a shorty loser. Youre obsessed with $IBRX X accounts that post 24x7 about $IBRX This is always my favorite"
X Link 2026-02-15T20:49Z 124K followers, 11.3K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing